Implementing decision aids affects care decisions in urology

After video-based decision aids were implemented for men with two common prostate conditions, rates of elective surgery for benign prostatic hyperplasia (BPH) and rates of active treatment for localized prostate cancer declined over 6 months. But the total cost of health care for those patients did not fall significantly, according to a new report in the American Journal of Managed Care (2015;21[2]:e130-e140).

"Although professional societies emphasize the role of shared decision making in helping men make treatment decisions about BPH and prostate cancer, evidence is limited about the impact of integrating decision aids into clinical practice to support this approach," said study leader David Arterburn, MD, MPH, a general internist and associate investigator at Group Health Research Institute in Seattle, Washington.

"We found that implementing video-based decision aids for BPH and localized prostate cancer in a large, multisite urology group practice setting was associated with fewer men with medically treated BPH choosing to undergo elective surgical intervention and fewer men with localized prostate cancer choosing to undergo hormonal, surgical, or radiation treatment," Arterburn added.

For men with medically treated BPH (that is, those who were already receiving prescription medications to treat their BPH), the study found the rate of surgical intervention for BPH declined by 32%; but for those with untreated BPH, the rate did not fall significantly. For men with localized prostate cancer, rates of active treatment declined by 27%.

The study found a trend toward lower total health care costs after decision aid introduction for these conditions, but this finding was not statistically significant. Possible reasons include small sample sizes, Arterburn said, even though this observational study included more than 4,000 patients. Another possible reason is that choosing nonsurgical treatment for BPH and active surveillance for localized prostate cancer may generate costs related to follow-up and testing.

This study is part of the largest study to-date of implementing patient decision aids in the context of quality improvement for urologic care.

This implementation and evaluation were part of Group Health's large-scale quality-improvement program, which has achieved the world's largest distribution of video-based decision aids for any single organization. Since 2009, Group Health has used a multimodal strategy to give patients more than 50,000 video-based decision aids in 12 preference-sensitive health conditions in six specialties.

In cases of BPH, which becomes more common with age, the prostate is enlarged without raising cancer risk. Localized prostate cancer is disease that has not been found to have spread throughout the body.

For both BPH and localized prostate cancer, no single treatment has been conclusively shown to be best, long-term outcome evidence is limited, alternative treatment options have varying benefit-risk profiles, and informed patients may choose to avoid any treatment whatsoever.

"That means patients with both BPH and localized prostate cancer are good candidates for shared decision making conversations," Arterburn said. Decision aids help patients who are at a crossroad: deciding which treatment to pursue when a health condition is in a clinical gray area with more than one treatment option, each with pros and cons and with little evidence to say any one option is better than another.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs